<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512807</url>
  </required_header>
  <id_info>
    <org_study_id>Dr. Atyaf Aldawodi</org_study_id>
    <nct_id>NCT04512807</nct_id>
  </id_info>
  <brief_title>AMH and Pregnancy Outcome in IVF</brief_title>
  <official_title>Low Anti-mullerian Hormone and Pregnancy Outcome in IVF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al Baraka Fertility Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al Baraka Fertility Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-Mu¨llerian hormone (AMH) is an established marker of ovarian reserve (La Marca et al.,&#xD;
      2010; Nelson et al., 2009) and predicts both high and low responses in ovarian stimulation&#xD;
      cycles (Eldar-Geva et al., 2005; Nardo et al., 2009; Nelson et al., 2007). Presently, AMH&#xD;
      helps clinicians counsel patients prior to IVF treatment (La Marca et al., 2011), despite the&#xD;
      fact that it fails to predict who will become pregnant (Lamazou et al., 2011; Riggs et al.,&#xD;
      2011). It has been demonstrated that poor responders can achieve both pregnancy and live&#xD;
      birth (Weghofer et al., 2011). There are few studies regarding extremely low AMH&#xD;
      concentrations and live births (Fraisse et al., 2008; Tocci et al., 2009; Weghofer et al.,&#xD;
      2011) and they present either a small number of patients or limited data describing the&#xD;
      groups of investigated patients. Another factor affecting pregnancy rates is endometriosis, a&#xD;
      chronic gynaecological disease characterized by the presence of functional endometrial tissue&#xD;
      outside the uterine cavity (Koninckx et al., 1991). Many studies have reported that pregnancy&#xD;
      rates are lower in women with endometriosis than in controls (Gupta et al., 2008; Koninckx et&#xD;
      al., 1991 Pellicer et al., 2000). Lower AMH serum concentrations are associated with&#xD;
      endometriosis severity (Shebl et al., 2006). The primary objective of the present study was&#xD;
      to assess the clinical pregnancy rates in women with extremely low AMH concentrations with&#xD;
      respect to age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">November 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy test</measure>
    <time_frame>2 weeks</time_frame>
    <description>B-HCG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>fetal heart activity</description>
  </primary_outcome>
  <enrollment type="Anticipated">650</enrollment>
  <condition>AMH</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>AMH</intervention_name>
    <description>AMH &amp; PREGNANCY</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with low or very low AMH&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women ≥22 years age AMH is 0.5 and less Body mass index- 18.5-30 kg/m 2 The normal uterine&#xD;
        cavity on ultrasound scan At least one good quality embryo present for transfer Women&#xD;
        willing to comply with the clinical study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women ≥ 45 years age&#xD;
&#xD;
          -  AMH &gt;0.5&#xD;
&#xD;
          -  Uterine abnormalities that can compromise the IRs (e.g., endometrial polyp, fibroids,&#xD;
             hydrosalpinx, and adenomyosis)&#xD;
&#xD;
          -  Endocrine dysfunction or organ dysfunction such as liver or kidney failure.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al Baraka Fertility Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Kamal Rageh</investigator_full_name>
    <investigator_title>doctor , medical director</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

